|
1) Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-78
|
|
|
|
2) Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007; 297: 499-508
|
|
|
|
|
|
3) Amarenco P, Bogousslavsky J, Callahan A, et al. The Stroke Prevention by Aggressive Reduction in Cholesterol Level (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549-59
|
|
|
|
|
|
4) 日本脳卒中学会. 脳卒中治療ガイドライン2009
|
|
|
|
|
|
5) Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-207
|
|
|
|
|
|
6) Wanner C, Krane V, Marz W, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hem dialysis. N Engl J Med. 2005; 353: 238-42
|
|
|
|
|
|
7) Fellstrom, Alan G, Jardine AG, et al. AURORA Study Group: Rosuvastatin and cardiovascular events in the patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-407
|
|
|
|
|
|
8) Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357: 2248-61
|
|
|
|
|
|
9) Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of Rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 1231-9
|
|
|
|
|
|
10) The ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-74
|
|
|
|
|
|
11) Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375: 1875-84
|
|
|
|
|
|
12) Flory JH, Ellenberg S, Szaparty PO, et al. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care. 2009; 32; 547-51
|
|
|
|
|
|
13) Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359: 1343-56
|
|
|
|
|
|
14) Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus statin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am Heart J. 2008; 156: 826-32
|
|
|
|
|
|
15) Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int Suppl. 2003; 84: S207-10
|
|
|
|
|
|
16) Shepherd J, Cobbe SM, Ford I, et al. The west of Scotland coronary prevention study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301-7
|
|
|
|
|
|
17) Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-9
|
|
|
|
|
|
18) Plehn JF, Davis BR, Smelt AH et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999; 99: 216-23
|
|
|
|
|
|
19) Prevention of Cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339: 1349-57
|
|
|
|
|
|
20) Sever PS, Dahlof B, Pouler NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in Anglo-Scandinavian Cardiac Outcome Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58
|
|
|
|
|
|
21) Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685-96
|
|
|
|
|
|
22) Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomised controlled trial. JAMA. 2001; 285: 1711-8
|
|
|
|
|
|
23) Cannon CP, Braunwald E, MMcCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med. 2004; 350: 1495-504
|
|
|
|
|
|
24) Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999; 341: 70-6
|
|
|
|
|
|
25) LaRosa JC, Grundy SM, Water DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Engl J Med. 2005; 352: 1425-35
|
|
|
|
|
|
26) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controled trial. Lancet. 2002; 360: 7-22
|
|
|
|
|
|
27) Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009; 8: 453-63
|
|
|
|
|
|
28) Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008; 39: 3297-302
|
|
|
|
|
|
29) Strippoli GF, Navaneethan SD, Johnson DW, et al. Effect of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008; 336: 645-51
|
|
|
|
|
|
30) Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009; 54: 810-9
|
|
|
|
|
|
31) Holdaas H, Fellstrom B, Jardine Ag, et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre randomized, placebo-controlled trial. Lancet. 2003; 361: 2024-31
|
|
|
|
|
|
32) 日本腎臓病学会, 編. CKD診療ガイド2009. 東京医学社; 2009. p.69-70
|
|
|
|
|
|
33) Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010; 375: 735-42
|
|
|
|
|
|
34) The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005; 366: 1849-61
|
|
|
|
|
|
35) Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32: 493-8
|
|
|
|
|
|
36) Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009; 373: 1780-8
|
|
|
|
|
|
37) Kastelein JP, Akdin F, Stroes ESG, et al. ENHANCE Investigators. Sinvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2010; 358: 1431-43
|
|
|
|
|
|
38) Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomised trial. JAMA. 2008; 299: 1678-89
|
|
|
|
|
|
39) Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008; 52: 2198-205
|
|
|
|
|
|
40) Peto R, Emberson J, Landray M, et al. Analysis of cancer data from ezetimibe trials. N Engl J Med. 2008; 359: 1357-66
|
|
|
|
|
|
41) Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002; 360: 1623-30
|
|
|
|
|
|
42) Ito H, Ouchi Y, Ohashi Y, et al. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the prevention anti-atherosclerosis trial in the elderly (PATE). J Atheroscl Thromb. 2001; 8: 33-44
|
|
|
|
|
|
43) Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009; 361: 2113-22
|
|
|
|
|